TFF3 and cancer: ,26 There is an argument that screening for TFF3 as a surrogate for IM may be limited by the reduction in goblet cells as BO progresses to cancer, however, our BEST2 trial showed that the sensitivity for TFF3 in the presence of dysplasia is not reduced by dysplastic grade.27